Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC and Secondary Cytoreduction for PARPi-Resistant Ovarian Cancer
NCT06544460Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in ovarian cancer, sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06544460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544460.